Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Accumulated Expenses (2016 - 2025)

Lineage Cell Therapeutics' Accumulated Expenses history spans 15 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 8.44% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, down 8.44%, while the annual FY2025 figure was $1.1 million, 8.44% down from the prior year.
  • Accumulated Expenses reached $1.1 million in Q4 2025 per LCTX's latest filing, up from $486000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $21.0 million in Q2 2022 to a low of $349000.0 in Q3 2023.
  • Average Accumulated Expenses over 5 years is $2.6 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 1474.21% in 2022, then crashed 97.23% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $2.2 million in 2021, then surged by 77.29% to $3.8 million in 2022, then fell by 18.52% to $3.1 million in 2023, then crashed by 61.67% to $1.2 million in 2024, then decreased by 8.44% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Accumulated Expenses are $1.1 million (Q4 2025), $486000.0 (Q3 2025), and $793000.0 (Q2 2025).